

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

EAGLE LEGEND ASIA

EAGLE LEGEND ASIA LIMITED

鵬程亞洲有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 936)

INSIDE INFORMATION LITIGATION INVOLVING A SUBSIDIARY

This announcement is made by Eagle Legend Asia Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On 25 November 2019, Vast Bloom Investment Limited (大旺投資有限公司) (the “**Subsidiary**”), an indirect 51% owned subsidiary of the Company, which holds a 80% equity interest in Guangdong Dahe Biological Technologies Limited* (廣東大合生物科技股份有限公司) (the “**Target**”), received a notice dated 19 November 2019 from the Intermediate People’s Court of Maoming City, Guangdong Province* (廣東省茂名市中級人民法院) (the “**Court**”) regarding the proceedings relating to the dispute among the shareholders initiated by the minority shareholders of the Target. The Subsidiary holds a 80% equity interest in the Target (the “**Court Proceedings**”). In response to the Court Proceedings, the Subsidiary petitioned to the Court for the winding-up of the Target on 4 December 2019. As at the date of this announcement, the Court Proceedings and the winding-up petition are in progress.

The Company will update its shareholders and investors if and when there is any material development in this regard. Shareholders and investors should exercise caution in dealing with the securities of the Company.

By order of the Board
Eagle Legend Asia Limited
Guo Peineng
Deputy Chairman

Hong Kong, 9 December 2019

As at the date of this announcement, the board of directors of the Company comprises Mr. Guo Peineng, Mr. Zhao Yi and Mr. Chen Huajie as executive directors; and Mr. Li Yongjun, Mr. Xu Xiaowu and Mr. Diao Yingfeng as independent non-executive directors.

* *For identification purpose only.*